Solfion

SHORT DESCRIPTION
Each vial Solfion® 125 mg Powder for IV/IM injection contains Methylprednisolone sodium succinate equivalent to Methylprednisolone 125 mg.

INDICATION

• Endocrine disorders : Primary or secondary adrenocortical insufficiency, acute adrenocortical insufficiency.
• Rheumatic disorders : As adjunctive therapy for short term administration in : Post traumatic osteoarthritis, synovitis osteoarthritis, rheumatoid arthritis, acute and sub-acute bursitis; epicondylitis, acute non-specific tenosynovitis, acute gouty arthritis, psoriasis arthritis, and ankylosing spondylitis.
• Collagen disease : During an exacerbation or as maintenance therapy is selected cases of systemic lupus erythematosus, systemic dermatomyositis and acute rheumatic carditis.
• Dermatologic disease : Pemphigus, severe erythema multiform, exfoliate dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis, and mycosis fungoides.
• Allergic states : Bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions.
• Gastrointestinal disease : TO tide the patient over a critical period of the disease in ulcerative colitis and regional enteritis.
• Neoplastic disease : For palliative management of leukemia and lymphomas in adults and acute leukemia of childhood.
• Edematous states : To induce diuresis or remission of preoteinuria in the nephritic syndrome, without uremia, of the idiophatic type or that due to lupus erythematosus.
• Nervous system : Acute exacerbation of multiple sclerosis.

SPECIFICATION
Solfion® Powder for IV/IM Injection 125 mg
Box, 1 vial @ 125 mg + 1 ampoule solvent @ 2 ml